Crescent Biopharma (CBIO) Treasury Shares (2014 - 2026)

Crescent Biopharma (CBIO) has 13 years of Treasury Shares data on file, last reported at $74701.0 in Q1 2026.

• Treasury Shares for Q1 2026 came in at $74701.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $74701.0 (changed N/A YoY), and the FY2025 annual result was $741454.0, up 1440.43% from the prior year.
• Treasury Shares fell to $74701.0 in Q1 2026 per CBIO's latest filing, from $741454.0 in the prior quarter.
• Over five years, Treasury Shares peaked at $741454.0 in Q4 2025 and troughed at $48133.0 in Q3 2024.
• A 5-year average of $196390.6 and a median of $120282.5 in 2023 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2025: Treasury Shares tumbled 63.43% in 2022, then jumped 810.78% in 2025.
• A 5-year view of Treasury Shares shows it stood at $204785.0 in 2022, then tumbled by 42.79% to $117157.0 in 2023, then surged by 110.62% to $246753.0 in 2024, then surged by 200.48% to $741454.0 in 2025, then plunged by 89.93% to $74701.0 in 2026.
• Business Quant data shows CBIO's Treasury Shares at $74701.0 in Q1 2026, $741454.0 in Q4 2025, and $438386.0 in Q3 2025.